康希诺：2023年营收3.57亿元，流脑疫苗产品销售收入增长266.39%至5.62亿元

财经网03-27

3月27日晚间，康希诺发布年度业绩报告称，2023年营业收入约3.57亿元，同比减少65.49%；归属于上市公司股东的净利润亏损约14.83亿元。报告期内，公司主营业务收入为疫苗及相关产品销售收入，境内收入为3.42亿元，占主营业务收入比重为99.09%。集团流脑疫苗产品销售收入较比处于商业化初期的去年同期大幅增长，实现销售收入5.62亿元，同比增长266.39%；新冠疫苗产品销售收入较去年同期...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422202994?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-27 21:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2422202994","market":"sh","top_or_hot":-1,"title":"康希诺：2023年营收3.57亿元，流脑疫苗产品销售收入增长266.39%至5.62亿元","media":"财经网","content":"<div>\n<p>3月27日晚间，康希诺发布年度业绩报告称，2023年营业收入约3.57亿元，同比减少65.49%；归属于上市公司股东的净利润亏损约14.83亿元。报告期内，公司主营业务收入为疫苗及相关产品销售收入，境内收入为3.42亿元，占主营业务收入比重为99.09%。集团流脑疫苗产品销售收入较比处于商业化初期的去年同期大幅增长，实现销售收入5.62亿元，同比增长266.39%；新冠疫苗产品销售收入较去年同期...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272118137a4f8678&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康希诺：2023年营收3.57亿元，流脑疫苗产品销售收入增长266.39%至5.62亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康希诺：2023年营收3.57亿元，流脑疫苗产品销售收入增长266.39%至5.62亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-27 21:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272118137a4f8678&s=b><strong>财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月27日晚间，康希诺发布年度业绩报告称，2023年营业收入约3.57亿元，同比减少65.49%；归属于上市公司股东的净利润亏损约14.83亿元。报告期内，公司主营业务收入为疫苗及相关产品销售收入，境内收入为3.42亿元，占主营业务收入比重为99.09%。集团流脑疫苗产品销售收入较比处于商业化初期的去年同期大幅增长，实现销售收入5.62亿元，同比增长266.39%；新冠疫苗产品销售收入较去年同期...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272118137a4f8678&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272118137a4f8678&s=b","article_id":"2422202994","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272118137a4f8678&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2422202994","pubTimestamp":1711545447,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"报告期内，公司主营业务收入为疫苗及相关产品销售收入，境内收入为3.42亿元，占主营业务收入比重为99.09%。同时，公司根据新冠疫苗产品的实际及预期退货情况，核算冲减报告期内相关收入2.53亿元及成本1.11亿元，并因报告期内新冠疫苗产量较低，相关产线产能利用率不足，集团将该部分冗余产能对应的固定成本2.51亿元计入营业成本。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"688185":"康希诺","06185":"康希诺生物"},"translate_title":"Kangxinuo: In 2023, the revenue was 357 million yuan, and the sales revenue of epidemic cerebrospinal meningitis vaccine products increased by 266.39% to 562 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"06185":0.9},"content_text":"3月27日晚间，康希诺发布年度业绩报告称，2023年营业收入约3.57亿元，同比减少65.49%；归属于上市公司股东的净利润亏损约14.83亿元。报告期内，公司主营业务收入为疫苗及相关产品销售收入，境内收入为3.42亿元，占主营业务收入比重为99.09%。集团流脑疫苗产品销售收入较比处于商业化初期的去年同期大幅增长，实现销售收入5.62亿元，同比增长266.39%；新冠疫苗产品销售收入较去年同期大幅下降，实现销售收入3665.63万元，较比去年同期下降96.86%。同时，公司根据新冠疫苗产品的实际及预期退货情况，核算冲减报告期内相关收入2.53亿元及成本1.11亿元，并因报告期内新冠疫苗产量较低，相关产线产能利用率不足，集团将该部分冗余产能对应的固定成本2.51亿元计入营业成本。（上交所）(编辑：周彤)关键字：","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422202994"}